Home
 
Sitemap
 
Legal Statement
 
 
 
 
 
 
 
 
 
Home > Products > Tracleer® > > About Tracleer > WHO functional class
 
Products
 
 
 
 
 
 
 
 
 
 
Tracleer®
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About PAH
 
 
 
 
 
 
 
 
 
 
 
 
Clinical worsening
 
 
Exercise capacity
 
 
Haemodynamics
 
 
Special patient population
 
 
Dosing regimen
 
WHO functional class
 
 
Long-term outcomes
 
 
Safety information
 
 
Effective patient management
 
 
References
 
 
Links of Interest
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zavesca®
 
 
 
Impact on symptoms by WHO functional class

  • Compared with placebo, patients treated with Tracleer® demonstrated an improvement in WHO functional class after 16 weeks2, which is maintained over time (figure 12)37

Figure 12: Tracleer maintains improvement of WHO functional class over time37


Last update: 11 Jul 2008